Free Trial
NASDAQ:HCWB

HCW Biologics (HCWB) Stock Price, News & Analysis

HCW Biologics logo
$0.77 +0.06 (+8.45%)
(As of 11/22/2024 ET)

About HCW Biologics Stock (NASDAQ:HCWB)

Key Stats

Today's Range
$0.63
$0.79
50-Day Range
$0.29
$1.24
52-Week Range
$0.28
$2.52
Volume
2.04 million shs
Average Volume
2.60 million shs
Market Capitalization
$29.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
21st Percentile Overall Score

HCWB MarketRank™: 

HCW Biologics scored higher than 21% of companies evaluated by MarketBeat, and ranked 865th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for HCW Biologics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of HCW Biologics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of HCW Biologics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.04% of the float of HCW Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    HCW Biologics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HCW Biologics has recently decreased by 67.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    HCW Biologics does not currently pay a dividend.

  • Dividend Growth

    HCW Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.04% of the float of HCW Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    HCW Biologics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HCW Biologics has recently decreased by 67.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    HCW Biologics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for HCW Biologics this week, compared to 0 articles on an average week.
  • Search Interest

    4 people have searched for HCWB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, HCW Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    49.90% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.96% of the stock of HCW Biologics is held by institutions.

  • Read more about HCW Biologics' insider trading history.
Receive HCWB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter.

HCWB Stock News Headlines

HCW Biologics Expands with New Financial Agreements
2025: Digital Asset Insights You Need to Know
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
HCW Biologics licenses proprietary preclinical molecule to WY Biotech
Why Is Penny Stock HCW Biologics Surging On Monday?
See More Headlines

HCWB Stock Analysis - Frequently Asked Questions

HCW Biologics' stock was trading at $1.2250 at the beginning of 2024. Since then, HCWB stock has decreased by 37.1% and is now trading at $0.77.
View the best growth stocks for 2024 here
.

HCW Biologics (HCWB) raised $45 million in an IPO on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton served as the underwriter for the IPO and Revere Securities was co-manager.

Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS).

Company Calendar

Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HCWB
Employees
40
Year Founded
N/A

Profitability

Net Income
$-24,990,000.00
Net Margins
-1,067.82%
Pretax Margin
-1,067.79%

Debt

Sales & Book Value

Annual Sales
$2.84 million
Book Value
($0.26) per share

Miscellaneous

Free Float
18,949,000
Market Cap
$29.12 million
Optionable
Not Optionable
Beta
0.83
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:HCWB) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners